
GRFS
Grifols SA
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
10.080
Open
9.990
VWAP
10.04
Vol
170.01K
Mkt Cap
6.83B
Low
9.990
Amount
1.71M
EV/EBITDA(TTM)
11.46
Total Shares
679.09M
EV
19.15B
EV/OCF(TTM)
15.92
P/S(TTM)
1.15
Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. The Company organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Its diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Its bio Supplies provides, mostly, biological products for non-therapeutic use.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
1.90B
+4.36%
--
--
1.91B
+6.27%
--
--
2.07B
+4.55%
--
--
Estimates Revision
The market is revising Downward the revenue expectations for Grifols, S.A. (GRFS) for FY2025, with the revenue forecasts being adjusted by -0.75% over the past three months. During the same period, the stock price has changed by 39.32%.
Revenue Estimates for FY2025
Revise Downward

-0.75%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward

+1.43%
In Past 3 Month
Stock Price
Go Up

+39.32%
In Past 3 Month
1 Analyst Rating

2.54% Upside
Wall Street analysts forecast GRFS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GRFS is 10.30 USD with a low forecast of 10.30 USD and a high forecast of 10.30 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
1 Hold
0 Sell
Hold

2.54% Upside
Current: 10.045

Low
10.30
Averages
10.30
High
10.30

2.54% Upside
Current: 10.045

Low
10.30
Averages
10.30
High
10.30
JPMorgan
James Gordon
Neutral
maintain
2025-06-18
Reason
JPMorgan
James Gordon
Price Target
2025-06-18
maintain
Neutral
Reason
JPMorgan analyst James Gordon raised the firm's price target on Grifols to $10.30 from $7.60 and keeps a Neutral rating on the shares.
JPMorgan
Neutral
maintain
2025-06-18
Reason
JPMorgan
Price Target
2025-06-18
maintain
Neutral
Reason
JPMorgan raised the firm's price target on Grifols to EUR 12 from EUR 9.50 and keeps a Neutral rating on the shares.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Grifols SA (GRFS.O) is 9.38, compared to its 5-year average forward P/E of 17.64. For a more detailed relative valuation and DCF analysis to assess Grifols SA 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Undervalued
5Y Average PE
17.64
Current PE
9.38
Overvalued PE
24.14
Undervalued PE
11.14
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Undervalued
5Y Average EV/EBITDA
12.54
Current EV/EBITDA
9.96
Overvalued EV/EBITDA
15.06
Undervalued EV/EBITDA
10.02
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair
5Y Average PS
1.43
Current PS
0.94
Overvalued PS
2.12
Undervalued PS
0.73
Financials
Annual
Quarterly
FY2024Q4
YoY :
+10.68%
2.11B
Total Revenue
FY2024Q4
YoY :
+67.14%
407.41M
Operating Profit
FY2024Q4
YoY :
+87.79%
100.18M
Net Income after Tax
FY2024Q4
YoY :
+22.22%
0.11
EPS - Diluted
FY2024Q4
YoY :
+706.27%
396.58M
Free Cash Flow
FY2024Q4
YoY :
-0.77%
38.79
Gross Profit Margin - %
FY2024Q4
YoY :
-657.58%
7.36
FCF Margin - %
FY2024Q4
YoY :
-4.07%
4.24
Net Margin - %
FY2024Q4
YoY :
-16.92%
2.21
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 986.97% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
89.2K
Volume
1
6-9
Months
8.2K
Volume
1
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
2
1.9M
Volume
Months
6-9
6
7.3M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
GRFS News & Events
Events Timeline
2025-05-30 (ET)
2025-05-30
06:11:45
U.S. court rules to go on with Grifol lawsuit against Gotham City, Reuters says


2025-05-12 (ET)
2025-05-12
11:45:41
Grifols reaffirms guidance for 2025

2025-05-12
11:43:43
Grifols reports Q1 adjusted EBITDA of EUR 400M, up 14.2% from last year

Sign Up For More Events
Sign Up For More Events
News
2.0
07-09BenzingaVerona Pharma, Rhythm Pharmaceuticals, AES And Other Big Stocks Moving Higher On Wednesday
6.5
06-24NASDAQ.COMAnalysts Anticipate KOMP To Hit $60
4.0
06-17BenzingaJP Morgan Maintains Neutral on Grifols, Raises Price Target to $10.3
Sign Up For More News
People Also Watch

DRH
Diamondrock Hospitality Co
8.110
USD
+0.62%

IART
Integra Lifesciences Holdings Corp
12.550
USD
-1.26%

SID
Companhia Siderurgica Nacional SA
1.570
USD
0.00%

JAMF
Jamf Holding Corp
8.100
USD
-0.37%

LZB
La-Z-Boy Inc
37.820
USD
-0.45%

CMPR
Cimpress PLC
48.390
USD
-0.17%

HPK
Highpeak Energy Inc
9.370
USD
-0.32%

IQ
iQIYI Inc
2.010
USD
-1.47%

LC
LendingClub Corp
12.920
USD
-1.90%

CABO
Cable One Inc
139.970
USD
-8.37%
FAQ

What is Grifols SA (GRFS) stock price today?
The current price of GRFS is 10.045 USD — it has increased 1.06 % in the last trading day.

What is Grifols SA (GRFS)'s business?

What is the price predicton of GRFS Stock?

What is Grifols SA (GRFS)'s revenue for the last quarter?

What is Grifols SA (GRFS)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Grifols SA (GRFS)'s fundamentals?

How many employees does Grifols SA (GRFS). have?
